On April 2, UBS purchased an additional 13.9545 million shares of LUYE PHARMA (02186) at HK$2.8547 per share, involving a total consideration of approximately HK$39.84 million. Following this transaction, UBS's total holdings in the company reached approximately 403 million shares, representing a 10.09% stake. Additional information: 218,500,000 of the reported long and short positions relate to the securities lending agreement executed in connection with the convertible bond issuance disclosed on June 28, 2023.